Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) have earned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $96.58.

ITCI has been the subject of a number of analyst reports. Mizuho raised their price target on Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. Royal Bank of Canada dropped their price target on shares of Intra-Cellular Therapies from $107.00 to $106.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. JPMorgan Chase & Co. increased their price objective on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Cantor Fitzgerald raised their price objective on shares of Intra-Cellular Therapies from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Finally, UBS Group cut their target price on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th.

Insider Transactions at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 34,396 shares of Intra-Cellular Therapies stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $77,962,764.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intra-Cellular Therapies news, Director Rory B. Riggs sold 4,462 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $75.57, for a total transaction of $337,193.34. Following the completion of the sale, the director now owns 116,600 shares in the company, valued at $8,811,462. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Sharon Mates sold 34,396 shares of Intra-Cellular Therapies stock in a transaction on Friday, August 30th. The shares were sold at an average price of $72.84, for a total value of $2,505,404.64. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $77,962,764.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 199,778 shares of company stock valued at $14,892,738. 3.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Intra-Cellular Therapies

A number of institutional investors have recently added to or reduced their stakes in the stock. Kapitalo Investimentos Ltda purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter valued at about $26,000. Headlands Technologies LLC purchased a new stake in Intra-Cellular Therapies during the first quarter valued at approximately $32,000. Fidelis Capital Partners LLC purchased a new position in Intra-Cellular Therapies in the first quarter worth $53,000. Summit Securities Group LLC acquired a new position in shares of Intra-Cellular Therapies during the second quarter worth $56,000. Finally, Cape Investment Advisory Inc. acquired a new position in shares of Intra-Cellular Therapies during the fourth quarter worth $78,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Up 0.2 %

Shares of NASDAQ ITCI opened at $75.38 on Wednesday. Intra-Cellular Therapies has a 12-month low of $45.50 and a 12-month high of $84.89. The firm’s 50-day moving average price is $75.66 and its 200-day moving average price is $71.24. The stock has a market capitalization of $7.97 billion, a price-to-earnings ratio of -64.98 and a beta of 1.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. The business had revenue of $161.40 million for the quarter, compared to the consensus estimate of $157.74 million. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The company’s quarterly revenue was up 45.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.45) earnings per share. On average, equities analysts predict that Intra-Cellular Therapies will post -0.59 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.